STOCK TITAN

Fortrea Holdings (FTRE) 10-K Filings

FTRE NASDAQ

Here are the 10-K annual reports from Fortrea Holdings Inc. (FTRE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow FTRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTRE filings page.

Rhea-AI Summary

Fortrea Holdings Inc. is a global contract research organization providing phase I–IV clinical trial management, clinical pharmacology and consulting services to pharmaceutical, biotechnology and medical device companies. The company operates in about 100 countries with approximately 14,300 employees and one reporting segment, Clinical Services.

Fortrea, spun off from Labcorp, highlights strengths in oncology, where 40% of 2025 full-service therapeutic revenue came from oncology studies, and an estimated $41 billion addressable share of a forecast ~$145 billion 2026 clinical development market. It notes customer concentration, funding dependence, regulatory, data privacy, technology and cybersecurity risks as key challenges.